Hemrajani Rekha's Insider Trades & SAST Disclosures
Hemrajani Rekha's most recent trade in Alx Oncology Holdings Inc was a trade of 40,400 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Hemrajani Rekha.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 40,400 | 40,400 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Hemrajani Rekha | Director | Purchase of securities on an exchange or from another person at price $ 1.55 per share. | 02 Dec 2024 | 30,000 | 33,000 | - | 1.5 | 46,404 | Common Stock |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 20,200 | 20,200 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 40,701 | 40,701 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 21,367 | 21,367 | - | 0 | Common Stock | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 28,497 | 28,497 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc. | Rekha Hemrajani | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 17 Apr 2024 | 3,000 | 3,000 | - | 18 | 54,000 | Common Stock |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 20,200 | 20,200 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 12,004 | 12,004 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 12,004 | 12,004 | - | - | Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Rekha Hemrajani | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 21 Jul 2020 | 3,000 | 3,000 | - | 19 | 57,000 | Common Stock |
| Adverum Biotechnologies Inc | Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Aravive Inc | Rekha Hemrajani | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Apr 2020 | 42,750 | 14,250 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges